The Safety of EXPAREL ® (Bupivacaine Liposome Injectable Suspension) Administered by Peripheral Nerve Block in Rabbits and Dogs by Richard, Brigitte M. et al.
Hindawi Publishing Corporation
Journal of Drug Delivery
Volume 2012, Article ID 962101, 10 pages
doi:10.1155/2012/962101
Research Article
TheSafetyofEXPAREL  (BupivacaineLiposome
Injectable Suspension) Administered by Peripheral Nerve
BlockinRabbits and Dogs
BrigitteM. Richard,1 Paul Newton,2 LauraR.Ott,2 DeanHaan,2 Abram N. Brubaker,2
PhaedraI.Cole,2 PaulE.Ross,2 Marlon C. Rebelatto,2 andKeithG. Nelson2
1Clinical Research and Drug Safety Assessment, Pacira Pharmaceuticals, Inc., 10450 Science Center Drive, San Diego,
CA 92121, USA
2MPI Research Laboratories, North Main Street, Mattawan, MI 49071, USA
Correspondence should be addressed to Brigitte M. Richard, brigitter@pacira.com
Received 20 July 2011; Accepted 4 October 2011
Academic Editor: Guru V. Betageri
Copyright © 2012 Brigitte M. Richard et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
A sustained-release DepoFoam injection formulation of bupivacaine (EXPAREL, 15mg/mL) is currently being investigated for
postsurgical analgesia via peripheral nerve block (PNB). Single-dose toxicology studies of EXPAREL (9, 18, and 30mg/kg),
bupivacaine solution (Bsol, 9mg/kg), and saline injected around the brachial plexus nerve bundle were performed in rabbits
and dogs. The endpoints included clinical pathology, pharmacokinetics, and histopathology evaluation on Day 3 and Day 15
(2/sex/group/period). EXPAREL resulted in a nearly 4-fold lower Cmax versus Bsol at the same dose. EXPAREL was well tolerated
at doses up to 30mg/kg. The only EXPAREL-related eﬀect seen was minimal to mild granulomatous inﬂammation of adipose
tissue around nerve roots (8 of 24 rabbits and 7 of 24 dogs) in the brachial plexus sites. The results indicate that EXPAREL was well
tolerated in these models and did not produce nerve damage after PNB in rabbits and dogs.
1.Introduction
Bupivacaine is a local anesthetic/analgesic widely used in
the perioperative and postsurgical settings. Bupivacaine so-
lutions have been used for many years by multiple routes
for the relief of postoperative pain [1]. With technology now
allowing for directly visualizing a peripheral nerve prior to
injection, perineural nerve block, including brachial plexus
nerve block, has become increasingly popular.
T h eb r a c h i a lp l e x u si sal a r g e ,c o m p l e xb u n d l eo fn e r v e s
(arising from the nerve roots C5-T1). A single injection of
local anesthetic around the brachial plexus nerve bundle
resultsinblockofarmtissueinnervatedbyseveralperipheral
nerves. Several approaches to the brachial plexus blockade
have been described (i.e., the axillary, infraclavicular, supr-
aclavicular, and interscalene) and each have advantages in
certain situations. Stabilization of the needle for catheter
insertion after brachial plexus blockade is localized and is a
challenging aspect of this technique [2].
Brachial plexus blockade may require dispersion of a rel-
ativelylargevolumeofbupivacaineinsolutiontoaccomplish
blockade of the entire plexus. Complications may include
infection, hematoma, vascular puncture, toxicity, injury,
and total spinal anesthesia [3]. After performing the block
procedure, peripheral nerves may be damaged from pro-
longed contact with concentrated formulations [4, 5]. From
a systemic standpoint, high doses of bupivacaine may be
associated with a wide range of systemic complications, such
as central nervous and cardiovascular eﬀects [6].
A formulation of bupivacaine that provides prolonged
release of the active ingredient after a single administration
wouldsimplifypainmanagementinthepostoperativeperiod
and eliminate the undesired peak plasma concentrations as a
result of excessively high concentrations and reduce the risk
of local and systemic reactions [7].
EXPAREL (bupivacaine liposome injectable suspension)
is a sterile suspension of multivesicular liposomes using2 Journal of Drug Delivery
proprietary DepoFoam formulation technology to release
bupivacaine over several days. EXPAREL, the proposed pro-
prietary name, was designed to provide prolonged analgesia
for 72 hours after wound inﬁltration in patients [8].
Although diﬀerent liposomal formulations have been
administered to humans without toxicity [9], the in vivo
tolerability of liposomes continues to be investigated. Our
goal was to evaluate the potential local and systemic toxicity
of EXPAREL after a bolus injection into the brachial plexus
(i.e., a large, complex bundle of nerves in the shoulder).
Speciﬁcally, the study was designed to assess whether
EXPAREL did not produce nerve damage in the setting of
peripheral nerve block by comparison with unencapsulated
bupivacaine or saline control.
2.MaterialsandMethods
2.1. Materials
2.1.1. Description of DepoFoam Technology. The DepoFoam
drug-delivery system is a proprietary, injectable technology
that provides a sustained release of therapeutic compounds.
The DepoFoam system consists of multivesicular liposomes
composed of hundreds to thousands of chambers per
particle, resembling a “honeycomb-like” matrix [10].
Such particles are to be distinguished from multilamellar
vesicles, also known as a multilamellar liposome, which con-
tain multiple concentric membranes within each liposome
particle [11, 12].
The DepoFoam particle components are naturally occur-
ring or synthetic analogues of common lipids, including
phospholipids (e.g., dierucoylphosphatidylcholine and di-
palmitoylphosphatidylglycerol), cholesterol, and triglyc-
erides (e.g., triolein and tricaprylin). The particles typically
consist of >97% water (with dissolved drug) and 1% to
3% lipids, and are expected to be fully biodegradable. The
DepoFoam particles are typically suspended in isotonic
solutions containing sodium chloride 0.9% in water for
injection. The DepoFoam drug-delivery system is already
used in two marketed products, DepoDur and DepoCyt,
which are produced by Pacira Pharmaceuticals, Inc.
2.1.2. Description of DepoFoam Bupivacaine. DepoFoam bu-
pivacaine (bupivacaine liposome injectable suspension),
was supplied by Pacira Pharmaceuticals, Inc., San Diego,
California, USA. This formulation was previously designated
SKY0402.
The manufacture of DepoFoam particles has been pre-
viously described [12]. Brieﬂy, the process involves a double
emulsiﬁcationprocesswherethebupivacaineisaddedaspart
oftheinitialemulsiﬁcationprocess.Theamountofunencap-
sulated bupivacaine is controlled as part of the process and is
generally less than 10%. In DepoFoam Bupivacaine, one of
the speciﬁc lipids in the ﬁnal formulation is dierucoylphos-
phatidylcholine, EXPAREL was initially formulated at two
diﬀerent dose concentrations (15 and 25mg/mL in 0.9%
saline, expressed as anhydrous bupivacaine HCl equivalent).
The 15-mg/mL formulation is intended for commercial use.
The 15mg/mL of bupivacaine is the bupivacaine salt HCl;
it is chemically equivalent to 13.3mg/mL bupivacaine free
base. The 25-mg/mL formulation is a concentrated version
and was intended to increase exposure of local tissues to
relatively higher concentrations of both the active drug and
DepoFoam matrix.
2.1.3. Reference Product. Sensorcaine-MPF (methyl paraben
free; bupivacaine HCl injection, USP) 0.75% bupivacaine
solution, is manufactured by AstraZeneca, Wilmington,
Delaware, USA.
2.1.4. Control Article. Saline (0.9% sodium chloride injec-
tion, USP) is manufactured by Abbott Laboratories, North
Chicago, lllinois, USA.
2.1.5. Animals. New Zealand White rabbits and beagle dogs
wereorderedfromCovanceResearchProducts,Philadelphia,
Pennsylvania, and Kalamazoo, Michigan, USA, respectively.
The animals were 5 and half months (rabbit) and 5 to 6
months (dog) of age on arrival.
A total of 40 rabbits (20 males and 20 females) weighing
2.6 to 3.7kg and 40 dogs (20 males and 20 females) weighing
6.2 to 9.7kg, were used. Individual body weights were within
20% of the mean body weight for each gender.
2.2. Methods
2.2.1. Study Protocols. These pivotal studies were conducted
according to International Conference on Harmonisation
guidelines in accordance with Good Laboratory Practices
principles [13] as set forth by the United States Food and
Drug Administration 21 CFR Part 58 and in accordance
with single-dose acute toxicity testing for pharmaceuticals
[14]. All protocols were reviewed and approved by the
Institutional Animal Care and Use Committee of MPI
Research for compliance with regulations prior to study
initiation.
T h eb r a c h i a ln e r v eb l o c kp r o c e d u r ew a sp e r f o r m e di na n
MPI Research surgical suite using aseptic technique. General
anesthesia was induced and maintained with isoﬂurane to
eﬀect delivered in oxygen through a facemask. Each dose
was administered by nerve block once on Day 1. A 22g
3.5inch needle was used to perform a brachial plexus
nerve block in the left thoracic limb [15]. After placement
the needle was slowly withdrawn while each treatment
was injected. The animals were closely monitored during
anesthetic recovery for physiological disturbances includ-
ing cardiovascular/respiratory depression, hypothermia, and
excessive bleeding from the injection site.
Using a standard, by weight, block randomization proce-
dure, 20 males and 20 females were assigned to ﬁve groups
in each study. Each group consisted of 4 males and 4 females.
Groups 1, 2, and 3 received EXPAREL 9, 18, and 25mg/kg
(or 30mg/kg), respectively. Group 4 received bupivacaine
solution 9mg/kg, Group 5 received saline.
In rabbits, EXPAREL was administered at a dose volume
of 0.6, 1.2, and 1.2mL/kg, respectively. In dogs, EXPAREL
wasadministeredatadosevolumeof0.6,1.2,and1.0mL/kg,Journal of Drug Delivery 3
respectively. (The dogs intended for the 30mg/kg group
were erroneously administered only 1.0mL/kg (25mg/mL)
resulting in a dose level of 25mg/kg.) Bupivacaine solution
and saline control was administered at a dose volume of
1.2mL/kg in each species.
Following dose administration, animals were observed
without further treatment. Four animals (2 males and 2
females) in each group were sacriﬁced on Day 3, and the
remainder (designated as recovery animals, 2 males and 2
females)wereobservedforanadditionaltwoweeksuntilDay
15 sacriﬁce.
Endpoints included physical examinations, clinical signs,
clinical pathology, hematology, organ weight, and histopa-
thology of a standard list of tissues (including injection sites)
on Day 3 and Day 15, as well as pharmacokinetics (PK) on
Day 1 through 96 hours postdosing.
2.2.2. Pharmacokinetic Data Analysis. Plasma bupivacaine
concentrations were measured using a validated LC/MS/MS
assay in rabbit and dog K3EDTA plasma in the concen-
trations ranging from 10.0 to 10,000ng/mL. The lower
quantitation limit was 10ng/mL.
The PK parameters were evaluated by a noncompart-
mental model using WinNonlin, version 5.0 (Pharsight
Corp., Mountain View, California). The PK parameters
were maximum plasma concentration (Cmax), time at
which the Cmax occurred (tmax), and area under the plasma
concentration-time data from time 0 to selected time point
(t)( A U C 0−t). The appropriate group mean values and
standard deviation were calculated from the individual data
(combined sexes). Statistical results of pairwise comparisons
between EXPAREL and bupivacaine solution groups were
reported at the 0.05 signiﬁcance levels using Student’s two-
tailed t-test.
2.2.3. Tissue Processing and Microscopic Evaluation. All ani-
mals had a complete necropsy examination. Organ weights
were recorded for the following organs prior to ﬁxation:
adrenal glands, brain, heart, kidneys, liver, lungs (with
bronchi), ovaries, spleen, testes, and thyroid. Paired organs
were weighed together.
A selection of routine tissues (approximately 70) includ-
ing gross lesions, injection sites and surgical wound tissues
were collected at necropsy from 2 males and 2 females
per group sacriﬁced on Day 3 and remaining 2 males
and 2 females on Day 15 (recovery group). Tissues were
trimmed, embedded, sectioned, and hematoxylin- and
eosin-stainedusingstandardprocedures.Allpathologyslides
were prepared by MPI Research Laboratories. The severity
of histological ﬁndings was graded on a scale of one to
four with 0 = none, 1 = minimal, 2 = mild, 3 = moderate,
and 4 = severe. All protocol-speciﬁed tissues were examined,
and grading/interpretations of ﬁndings were made by a
pathologist certiﬁed by the American College of Veterinary
Pathology.
The nerve plexus site was excised, and histopathological
preparations were prepared across the complete site. Nerve
plexus sites examined microscopically at the three sampling
s i t e sw i t ha sm u c hn e r v ea n dc o n n e c t i v et i s s u ea sp o s s i b l e
(proximal, middle, and distal to the injection sites).
Allchangesintheskinandunderlyingmuscletissuesand
o t h e ro r g a n sw e r er e c o r d e d .
Neurotoxicity was assessed primarily on a histopatholog-
ical level using light microscopic evaluation of hematoxylin-
and eosin-stained injection sites. Any neural changes
observed at the injection sites would typically be listed as
separate ﬁndings (such as degeneration or inﬂammation).
3. Results
3.1. Toxicology Results. In both rabbits and dogs, a single-
dose administration of EXPAREL was well tolerated even at a
large dose and concentration (up to 30mg/kg, 25mg/mL).
There were no discernable EXPAREL-related eﬀects on
hematology, clinical chemistry, or urinalysis parameters
(data not shown). Few sporadic changes were noted at
termination or recovery, but these eﬀects were considered
not toxicologically relevant, may be the results of biological
variability, and were not considered treatment-related.
Microscopic ﬁndings at the brachial plexus sites in male
and female rabbits and dogs (combined sexes) are shown in
Tables 1 and 2. Microscopic ﬁndings on Day 3 consisted of
granulomatous inﬂammation and hemorrhage; females also
had minimal subacute inﬂammation. On Day 15, brachial
plexus lesions included granulomatous inﬂammation and
hemorrhage; females also had minimal ﬁbrosis; males also
had subacute inﬂammation and mineralization.
The only EXPAREL-related eﬀect seen was minimal to
mild granulomatous inﬂammation of adipose tissue around
nerve roots (8 of 24 rabbits and 7 of 24 dogs) in brachial
plexus sites. Granulomatous inﬂammation was present in
4/12 rabbits on Day 3 or Day 15, and in only 1/12 dog
(Day 3) and 6/12 dogs (Day 15). Apart from granulomatous
inﬂammation observed at the injection sites, there was no
overall incidence or severity of lesions in the brachial plexus
between animals receiving EXPAREL and the saline control
or Bupivacaine solution groups. All other microscopic ﬁnd-
ings were considered incidental and unrelated to EXPAREL.
This change was characterized by aggregates of macro-
phages with abundant vacuolated cytoplasm (Figures 1(a)
and 1(b)). With the low incidence and severity of these
eﬀects, this reaction was considered a normal response to the
liposomes and not adverse. There was no other diﬀerence in
the incidence or severity of lesions between groups.
3.2. Pharmacokinetic Results. In rabbits, Cmax values were
dose dependent, averaging 106 ± 67.9, 363 ± 478 and 205 ±
60.4ng/mL for the three EXPAREL dose levels (9, 18, and
30mg/kg, resp.) (Figure 2(a)). As a result of the relatively
ﬂat nature of the concentration-time proﬁle over the ﬁrst 48
hours, the mean time to maximum plasma concentration,
tmax,v a r i e dc o n s i d e r a b l y:1 0 .3±10.3, 20.0±20.1, and 36.5±
23.0 hours for the three doses (Figure 2(b)). The AUC0–96h
values determined for each of the three doses were 2700 ±
781,5540 ± 2520, and 9370 ± 1170ng·h/mL indicating dose
proportionality.4 Journal of Drug Delivery
Table 1: Injection site microscopic ﬁndings in rabbits (combined sexes).
Day 3 Observations Severity
grade Saline EXP
9mg/kg
EXP
18mg/kg
EXP
30mg/kg
Bsol
9mg/kg
Brachial plexus,
distal
Hemorrhage minimal 0 0 1 0 1
m o d e r a t e 0110 0
Inﬂammation,
granulomatous minimal 0 3 1 1 0
Inﬂammation, subacute minimal 0 0 0 0 1
Brachial plexus,
middle
Hemorrhage minimal 0 2 0 1 0
m o d e r a t e 0100 0
Inﬂammation,
granulomatous minimal 0 1 1 3 0
Inﬂammation, subacute minimal 0 0 1 0 0
Brachial plexus,
proximal
Hemorrhage
minimal 0 0 1 1 0
m i l d0100 0
m o d e r a t e 0100 0
Inﬂammation,
granulomatous minimal 0 0 1 1 0
Inﬂammation, subacute minimal 0 1 1 0 0
Day 15
Brachial plexus,
distal
Hemorrhage
minimal 0 1 1 0 0
m i l d0011 0
m o d e r a t e 0001 0
Inﬂammation, subacute minimal 0 1 0 0 0
Brachial plexus,
middle
Fibrosis minimal 0 0 0 0 1
Hemorrhage minimal 0 1 1 0 2
m i l d0000 1
Inﬂammation,
granulomatous m i l d0010 0
Inﬂammation subacute minimal 0 1 0 0 0
Mineralization minimal 0 0 1 0 0
Brachial plexus,
proximal Hemorrhage
minimal 0 2 0 0 0
m i l d0111 0
m o d e r a t e 0000 1
EXP, EXPAREL (bupivacaine liposome injectable suspension); Bsol, bupivacaine solution.
Note: number of animals examined was 4/group on Day 3 or Day 15.
(a) Rabbit (b) Dog
Figure 1: Injection site ﬁndings (Day 3) in a female rabbit (a) or dog (b) of the EXPAREL 18mg/kg (a) and 25mg/kg (b) showing
granulomatous inﬂammation of adipose tissue. H&E 20X.Journal of Drug Delivery 5
Table 2: Injection site ﬁndings (Day 3 and Day 15) in dogs (combined sexes).
Day 3 Observations Severity
grade Saline EXP
9mg/kg
EXP
18mg/kg
EXP
25mg/kg
Bsol
9mg/kg
Brachial plexus,
distal
Degeneration/regeneration
myoﬁbers m i l d 0000 1
Hemorrhage, adipose tissue m i l d 0001 0
minimal 0 3 1 3 1
Inﬂammation, granulomatous,
adipose tissue minimal 0 0 1 1 0
Inﬂammation, subacute minimal 0 0 0 0 1
Brachial plexus,
middle
Degeneration/regeneration
myoﬁber m i l d 0000 1
Hemorrhage
minimal 0 4 0 1 0
m i l d 0121 0
m o d e r a t e 0000 0
Inﬂammation, granulomatous minimal 0 1 0 0 0
Brachial plexus,
proximal
Hemorrhage mild 0 1 2 1 0
Inﬂammation, adipose tissue,
subacute m i l d 0001 0
Day 15
Brachial plexus,
distal
Degeneration/regeneration
myoﬁbers m i l d 0000 1
Hemorrhage minimal 2 0 1 0 2
Brachial plexus,
middle
Cyst minimal 0 0 1 0 0
Fibrosis minimal 0 0 0 0 0
Hemorrhage minimal 1 1 1 2 0
m i l d 0000 1
Inﬂammation, granulomatous minimal 0 0 1 2 0
Brachial plexus,
proximal
Degeneration/regeneraton
myoﬁbers minimal 0 0 1 0 1
Hemorrhage minimal 0 1 1 0 1
Inﬂammation, granulomatous minimal 0 0 1 1 0
m i l d 0010 0
Refer to Table 1 footnote.
These results can be compared with the PK values found
for the bupivacaine solution administered at the lowest dose,
9mg/kg. The plasma bupivacaine concentration peaked
quickly and fell below the limit of detection by 48 hours. The
Cmax, tmax,a n dA U C 0–96h were 433±26.2ng/mL,2.25±2.50
hours and 1670 ±249ng·h/mL, respectively.
Indogsreceivingbupivacainesolution(9mg/kg),plasma
bupivacaine concentrations peaked quickly (tmax of 1.00 ±
0.00 hour, Cmax of 1490 ± 131ng/mL) and declined rapidly
thereafter (Figure 3(a)). Half-life was estimated to be 5.92 ±
2.51 hours. The AUC0–96h value was 6100 ±1520ng·h/mL.
Detectable plasma bupivacaine concentrations were
observed in most animals with the EXPAREL formulation
(9mg/kg)overtheentire96-hourstudyperiod(Figure 3(b)).
The bupivacaine plasma concentrations declined slowly over
time, and the Cmax values were dose dependent, averaging
402 ± 513, 715 ± 747, and 1130 ± 604ng/mL for the three
dose levels (9, 18, and 25mg/kg, resp.). The corresponding
AUC0–96h values were 7460 ± 1370, 18200 ± 8640, and
22600±13700ng·h/mL.Whencomparingtheresultsinboth
species, the peak concentrations were reduced and elevated
plasma drug concentrations were maintained for longer
periods with EXPAREL compared to bupivacaine solution
at the same dose (9mg/kg) in both species. Occasional
and expected diﬀerences in individual PK parameters were
present although not observed across all groups. Particularly,
due to the known variability in the absorption of bupiva-
caine,Cmax wasfoundtobehigherinoneofthethreeanimals
receiving the intermediate formulations (18mg/kg). In this
dose group, the individual plasma Cmax values were 1080,
162, 108, and 103ng/mL achieved at 4, 48, 24, and 4 hours
and 1790, 648, 239, and 181ng/mL at 1, 24, 24, and 2 hours,
in rabbits and dogs, respectively.
The attenuation of Cmax with EXPAREL (9mg/kg) was
4.1 and 3.7 fold in both rabbits and dogs (combined
sexes),respectively.Thediﬀerencewasstatisticallysigniﬁcant
compared to bupivacaine solution at the same dose (P<
0.05).6 Journal of Drug Delivery
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Figure 2: Mean pharmacokinetic proﬁle of EXPAREL in rabbits from 0–24 hours (a) and 0–96 hours (b).
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Figure 3: Mean pharmacokinetic proﬁle of EXPAREL in dogs from 0–24 hours (a) and 0–96 hours (b).
The AUC0–24h was statistically signiﬁcantly lower in dogs
with EXPAREL compared to bupivacaine solution (2860 ±
1400 versus 6020 ± 1380ng·h/mL, 2-fold diﬀerence, P<
0.05), while the corresponding values in rabbits were not
signiﬁcantly diﬀerent (1230 ± 536 versus 1620 ± 288ng·
h/mL).
The AUC0–96h was statistically signiﬁcantly greater in
rabbits with EXPAREL compared to bupivacaine solution
at the same dose (9mg/kg, 2700 ± 781 versus 1670 ±
249ng·h/mL (1.6 fold diﬀerence P<0.05), whereas the
corresponding values in dogs were not signiﬁcantly diﬀerent
(7460 ± 1370 versus 6100 ±1520ng·h/mL) in dogs.
4. Discussion
The ultimate goal is to design a liposomal bupivacaine for-
mulation which would produce maximum prolongation
of analgesia without causing local or systemic toxicity. In
our studies, we evaluated the local and systemic toxicity
produced by EXPAREL in comparison with bupivacaine
solution and saline after a single bolus injection around the
brachial plexus nerve bundle. Since the local and systemic
toxicity of bupivacaine solution is well known, our experi-
ment focuses on showing that EXPAREL did not cause overt
irritation or local tissue damage even when used at high dose
or concentration.Journal of Drug Delivery 7
This is the ﬁrst reported toxicology evaluation of
EXPAREL using brachial plexus block. We used both a clini-
calconcentrationof15mg/mLandahigherconcentrationof
25mg/mL for a total dosing up to 30mg/kg to demonstrate
a wider safety margin for both concentration and total
dosing of bupivacaine and lipid components. Brachial plexus
blockade was selected as the large network of nerve ﬁbers
which distributes the innervation of the upper extremity is
clinically relevant.
Neurological damage is a well-recognized side eﬀect of
local analgesics applied in high concentrations close to neu-
ronal structures such as peripheral nerves, nerve plexuses,
or the spinal cord [16]. Local analgesics do not cause any
direct nerve damage unless they are injected intraneurally
or given in higher concentrations than that which is com-
mercially available. Several diﬀerent laboratory models have
proven that all local analgesics can be neurotoxic but that
lidocaineandtetracainearepotentiallymoreneurotoxicthan
bupivacaine [17].
The pathogenesis of local analgesics-induced local tis-
sue toxicity is poorly understood. There appears to be a
relationship between concentration and neurotoxicity. In
1985, Ready et al. [18] evaluated the neurotoxic eﬀects of
single injections of local analgesics in rabbits. They reported
that spinal cord histopathology remained normal and that
persistent neurologic deﬁcits were not seen with clinically
used concentrations of tetracaine, lidocaine, bupivacaine,
or chloroprocaine. However, histopathologic changes and
neurologic deﬁcits did occur with higher concentrations
of tetracaine (1%, up to 8%) and lidocaine (8%, up to
32%). It was found that high concentrations of lidocaine
(and tetracaine) caused neural injury. Notably, in this
model, extensive neurologic impairment was not necessarily
accompanied by equally extensive lesions in the spinal cord
and nerve roots, thus demonstrating the need for multiple
models to fully assess neurotoxicity. Particularly, the highest
concentration of bupivacaine (3.3%) was not consistently
associated with comparable neural damage.
Peripheral nerve injury is a rare complication of regional
anesthesia. The pathogenesis of local analgesics-induced
local tissue toxicity is poorly understood. The mechanism
of this enhanced toxicity remains to be established, but it
may be related to an eﬀect of diverse vasoconstriction on
anesthetic exposure [19]. Ischemia is one of the possible
causative mechanisms which may result from changes in
peripheral blood ﬂow caused by a vasopressor adjuvant such
as epinephrine.
Some believe that this neurological damage is a result of
spinal cord ischemia either due to prolonged hypotension
during surgery or as a consequence of arterial constriction
resulting from the use of epinephrine in the local anesthetics
solution [20]. The use of additives in the solution also has
been implicated as contributing factors. The pressure of the
injected agent may cause nonspeciﬁc pressure-related nerve
damage.
An immune-mediated mechanism may be possible as
suggested by others [4, 16]. In Brummett’s study, rat sciatic
nerves were harvested at either 24 hours or 14 days after
injection and analyzed for perineural inﬂammation and
nerve damage. When compared with the saline control
group, the bupivacaine group had signiﬁcantly higher peri-
neural inﬂammation scores at 24 hours. Nerves in the bupi-
vacaine and dexmedetomidine group showed less perineural
inﬂammationat24hourswhencomparedtothebupivacaine
group.
The response to liposomes is well documented and de-
scribed as a normal foreign body reaction appearing in
parallel with liposome deposition. It is generally well ac-
cepted that liposomes containing natural phospholipids,
triglycerides, and cholesterol should not present any risk
of antigenicity, presumably due to their similarities with
biological membranes [21]. Natural phospholipids such as
phosphatidylcholines with neutral net charge in physiologic
conditions are used to construct liposomes that closely
resemble biologic membranes. This type of liposomes made
of naturally occurring phospholipids is generally considered
safe for parenteral use.
Certain types of liposomes may cause extensive tissue
damage. Particularly, those composed of lecithin-choles-
terol-dicetyl phosphate or lecithin-cholesterol-stearylamine
have been reported to cause widespread tissue necrosis,
epilepsy, and some deaths due to respiratory failure imme-
diately after injection in mice whereas liposomes composed
of phosphatidylcholine cholesterol-phosphatidic acid, or
dipalmitoyl phosphatidylcholine only, produced minimal
morphological changes and by the sixth day post-injection;
the histopathology was limited to the mechanical trauma
caused by the injection [22]. Published studies with Lipo-
Spheres containing tristearin and egg phosphatidylcholine
in rats have shown no evidence of nerve damage and very
little perineural inﬂammation or foreign body response
[23]. Similarly, multilamellar vesicles liposomes made of
egg yolk phosphatidylcholine and cholesterol-containing
bupivacaine have not been shown to produce histologic
lesions on peripheral nerves after either brachial plexus
injection [24] or intracerebral administration [25]. Mali-
novsky et al. has found that the incorporation of bupivacaine
into multivesicular liposomes devoid of phosphatidylcholine
hydrolysis products or oxidation compounds produce spinal
cord histopathologic changes not signiﬁcantly diﬀerent from
bupivacaine solution after intracisternal administration in
rabbits [26].
More recently, drug carriers such as cyclodextrins have
shown that the inclusion of bupivacaine 0.5% in hydrox-
ypropyl-[beta]-cyclodextrin in equal amounts produced
minimal histological alterations of the rat sciatic nerve 48
hours after intraneural injection [27].
During an investigation of the pharmacological activity,
cytotoxicity and local eﬀects of ropivacaine 0.125%, 0.25%,
and 0.5% concentrations encapsulated into large unilamellar
vesicles composed of egg phosphatidylcholine, cholesterol,
and alpha-tocopherol (4:3:0.07, mole %) compared with
drug solution showed that there was no morphological tissue
changesintheareaofinjectionandsparseinﬂammatorycells
were observed in only one of the animals treated with plain
solution or ropivacaine at 0.5% [28].
In sciatic-nerve block experiments in rats, S¨ oderberg et
al. [29] showed that after two weeks following perineural8 Journal of Drug Delivery
injection of various formulations containing 2.0%, 10%,
20%, 60%, or 80% of lidocaine:prilocaine 1:1 mixtures in
mediumchaintriglyceridescomparedtosaline,vehicle,2.0%
lidocaine:prilocaine solution and ethanol, pathological
changes in the sciatic nerves revealed that the formulations
60% or greater (and ethanol) had neurotoxic eﬀects, that
is, axonal swelling and neuronal degeneration, demyeliza-
tion, and myelin degeneration associated with moderate to
marked diﬀuse inﬂammation in both the epineural and
neuronaltissues.Thecellularinﬁltratewasmainlycomposed
of macrophages, lymphocytes, ﬁbroblasts/ﬁbrocytes, and oc-
casional giant cells.
In a similar study in rats, formulations containing 2%,
4%, 8%, 16%, 32%, or 64% of a mixture of bupivacaine
and lidocaine base 4:1 in medium-chain triglyceride were
evaluated, together with 0.5%, 1.0%, and 2.0% bupivacaine
HCl solutions, bupivacaine 4.2% or 7.0% in medium-chain
triglyceride, and 20% lidocaine base in a polar lipid vehicle
[30]. Histopathologic examination of sciatic nerves by light
microscopyrevealedslighttomoderatesignsofneurotoxicity
only after administration of the 64% formulation, a week
after dosing.
With regard to pathological eﬀects of EXPAREL on pe-
ripheral nerves, no remarkable ﬁndings were observed
using the standard hematoxylin- and eosin-staining method.
The brachial plexus sites analyzed for histopathological
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no evidence of adverse local reactions even at the high-
est concentration, 25mg/mL (30mg/kg dose). With the
exception of granulomatous inﬂammation, there were no
observations of abnormal gross pathology ﬁndings at the
site of drug administration or elsewhere, and no signiﬁcant
changes in blood chemistry or animal behavior beyond
those observed with Bupivacaine solution or saline. It is
postulated that macrophages phagocytosed liposome mate-
rial, as they would any other foreign material in tissues.
The increased presence of these cells was therefore not
unexpected; the transient local inﬂammatory response to
EXPAREL is a normal foreign body reaction appearing in
parallel with liposome deposition. In Boogaerst’s study in
rabbits, the systemic bupivacaine concentration were lower
during the ﬁrst 10 minutes (P<0.05) and higher after
24 hours (P<0.05) after brachial plexus injection of
2.5mg bupivacaine in 1mL of 0.25% multilamellar liposo-
mal bupivacaine made of PC and cholesterol (ratio 4:3)
compared to bupivacaine solution, while the Cmax was not
very diﬀerent between the two formulations (∼0.2µg/mL)
[31].
In our studies, the PK proﬁle displays an initial rise
(reﬂective of unencapsulated drug present in the aqueous
phase of EXPAREL) (i.e., outside of the particles) followed
by a curve typical of a slow release delivery system (as
aﬀorded by the DepoFoam delivery system). In both rabbits
and dogs, the peak plasma concentrations of bupivacaine
with EXPAREL were signiﬁcantly attenuated, that is, up to
approximately fourfold (9mg/kg; 106 versus 433 and 402
versus 1490ng/mL, resp.) compared with equivalent doses of
bupivacaine solution (9mg/kg, P<0.05).
Occasional spurious high Cmax values were observed
which accounted for the relatively larger deviation seen with
EXPAREL compared with bupivacaine solution. Although
the precise nature of the mechanism(s) involved are un-
known, there was no compelling evidence that this ﬁnding
was related to the speciﬁc formulation of bupivacaine used
(EXPAREL).
The twofold lower AUC0–24h with EXPAREL compared
to bupivacaine solution reﬂects a slower absorption in dogs
(2860 versus 6020ng·h/mL, P<0.05 while in rabbits, the
AUC0–24h values were not signiﬁcantly diﬀerent (1230 versus
1620ng·h/mL). Plasma concentrations of bupivacaine were
approximately similar or even more prolonged in rabbits
(1.6 fold diﬀerence in AUC0–96h P<0.05) consistent with
sustained release of EXPAREL. As the toxicity of bupivacaine
is known to be generally associated with its Cmax, the lower
Cmax observed with EXPAREL as compared to bupivacaine
solution at the same dose demonstrates potential safety
advantages with this liposomal formulation.
The rate of systemic absorption of local anesthetics
is dependent upon the total dose and concentration of
drug administered, the route of administration, and the
vascularity of the administration site. Absorption from the
site of injection depends on the blood ﬂow, the more
rapid the rate at which plasma concentrations increase and
the greater the peak concentration of the drug [7]. It is
also possible that the interanimal variability in the PK
response may be the consequence of unequal dispersion of
the dosing material through the injection site resulting in
packed material as well as drug-induced vasodilation so that
v a r i e da m o u n t so fd r u gw e r ea b s o r b e d .
In summary, a depot formulation with bupivacaine as
the active component and DepoFoam lipid carrier was tested
after PNB in rabbits and dogs. In the present studies, there
were no local signs of toxicity, including no histological
evidence for any increase in local reactions or general
exacerbations of bupivacaine toxicity after peripheral nerve
block. Particularly, there was no evidence of nerve damage
at doses up to 30mg/kg bupivacaine (more than threefold
higher doses of EXPAREL versus bupivacaine solution).
Bupivacaine did not impact directly on neural tissue, and
the ﬁndings of granulomatous inﬂammation were more
consistent with a nonspeciﬁc foreign—body type reaction
most likely mediated by the DepoFoam particles.
Importantly, the DepoFoam delivery system leads to a
slower release of the drug allowing a longer duration of
action and, from a toxicological standpoint, to a slower
uptake into the systemic circulation avoiding high plasma
concentrations.
5. Conclusions
In conclusion, a single administration of EXPAREL was
demonstrated to be safe by peripheral nerve block in rabbits
and dogs when tested in comparison with bupivacaine HCl
and saline. EXPAREL did not cause overt irritation or local
tissue damage even when injected at high dose or concentra-
tion around the brachial plexus nerve bundle.Journal of Drug Delivery 9
Additional studies are ongoing to further examine the
utility of this novel formulation by various routes (e.g., local
inﬁltration, epidural, and intra-articular).
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